Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Anti-Parkinson Drugs Market Size, Value And Growth Trajectory Through 2030
The anti-parkinson drugs market has shown consistent expansion in recent years. It is projected to expand from $10.96 billion in 2025 to $11.46 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.6%. This historical expansion can be attributed to several factors such as the growth of the aging population, a rise in Parkinson’s disease diagnoses, the established use of levodopa, enhancements in neurological care, and the continuing requirements for managing chronic diseases.
The anti-parkinson drugs market size is anticipated to expand significantly in the coming years, reaching $14.28 billion in 2030, driven by a compound annual growth rate (CAGR) of 5.6%. This projected growth throughout the forecast period stems from factors such as the increasing prevalence of neurodegenerative disorders, breakthroughs in neuroprotective drugs, the wider availability of transdermal therapies, improved healthcare accessibility, and a dedicated focus on enhancing quality of life. Notable trends during this period are expected to include a growing demand for dopaminergic therapies, an increased uptake of extended-release formulations, a heightened emphasis on symptom management, the development of more combination drug therapies, and advancements in drug delivery technologies.
Get A Free Sample Report With In-Depth Market Insights:
Anti-Parkinson Drugs Market Development Factors: What’s Supporting Demand?
The increasing incidence of mental health disorders is expected to propel the growth of the mental wellness market going forward. Mental health disorders represent a clinically substantial impairment affecting a person’s cognition, emotional regulation, or conduct. The rising prevalence of mental disorders stems from increased exposure to chronic stress and adverse life experiences that overwhelm individual coping mechanisms and trigger psychological dysfunction. This escalating incidence of mental disorders also expands the anti-Parkinson drugs market, as these medications assist in minimizing and curing mental disorders. For instance, in October 2025, the Institute for Health Metrics and Evaluation, a US-based health research organization, reported that 15% of the world’s population experienced mental disorders in 2023, and 17% of the total years lived with disability globally were attributed to mental disorders in the same year. Consequently, the high prevalence of mental disorder is driving the growth of the anti-Parkinson drugs market.
Anti-Parkinson Drugs Market Segmentation: How Does The Market Break Down By Category?
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine
Anti-Parkinson Drugs Market Transformation Trends: What Innovations Are Driving Change?
Companies active in the anti-Parkinson drugs market are prioritizing the development of advanced therapeutic solutions, such as those targeting motor fluctuations and dyskinesia, to improve symptom control and reduce undesirable side effects. Motor fluctuations and dyskinesia often pose significant challenges in treating Parkinson’s disease, impacting patient well-being. For example, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA. PRODUODOPA (foslevodopa/foscarbidopa) stands as the first subcutaneous 24-hour infusion therapy for advanced Parkinson’s disease, specifically designed to address severe motor fluctuations and dyskinesia when other treatments have failed. It works by continuously delivering levodopa, which may lead to an increase in ‘on’ time and better symptom management.
Anti-Parkinson Drugs Market Competitive Overview And Top Companies
Major companies operating in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.
View The Full Anti-Parkinson Drugs Market Report:
Anti-Parkinson Drugs Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
